

MEDIA MENTION

Bert Rein Discusses Free Speech Related to Promotion of Unapproved Drug Uses

Bloomberg Law - Pharma & Life Sciences News
December 4, 2018

Wiley Rein founding partner Bert W. Rein was quoted in a December 3 *Bloomberg Law - Pharma & Life Sciences News* article about a convicted drug-company ex-CEO who lost his last court appeal before the U.S. Supreme Court. The Court has twice declined to hear the case of the former executive who was convicted of wire fraud for his role in issuing a press release that publicized the use of a drug for a disease it wasn't approved to treat, according to *Bloomberg Law*.

"If there is a lesson, it might be that promoting a stock with false scientific information is no different from promoting with false financial information." Mr. Rein said.

What worsened the executive's position was that "there was no alleged patient benefit from (his) alleged distortion of trial results and no arguable benefit to patients or prescribers from his alleged activity," Mr. Rein said.

The article can be found here (*subscription may be required*).

Related Professionals

Bert W. Rein
Founder
202.719.7080
brein@wiley.law

Practice Areas

First Amendment/Commercial Speech